Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity

Dihydrofolate reductase (DHFR) is an established anti-cancer drug target whose inhibition disrupts folate metabolism and STAT3-dependent gene expression. Cycloguanil was proposed as a DHFR inhibitor in the 1950s and is the active metabolite of clinically approved plasmodium DHFR inhibitor Proguanil....

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jennifer I., Wang, Peng, Wong, Alan Y. L., Petrova, Boryana, Persaud, Rosanne, Soukhtehzari, Sepideh, Lopez McDonald, Melanie, Hanke, Danielle, Christensen, Josephine, Iliev, Petar, Wang, Weiyuan, Everton, Daniel K., Williams, Karla C., Frank, David A., Kanarek, Naama, Page, Brent D. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961069/
https://www.ncbi.nlm.nih.gov/pubmed/36837770
http://dx.doi.org/10.3390/metabo13020151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961069/
https://www.ncbi.nlm.nih.gov/pubmed/36837770
http://dx.doi.org/10.3390/metabo13020151

Ejemplares similares